news

Our latest
Press Releases & Updates

Latest press releases

RetinAI Expands Operations to Set Up a U.S. Office In Boston and Achieves 21 CFR Part 11 Compliance to Support Research and Clinical Studies

RetinAI, a leader in clinical and imaging data management software and advanced analytics for ophthalmology, is excited to announce the launch of its first U.S.-based office, located in Boston, MA. This expansion will support further growth within the U.S. market, building upon existing collaborations with U.S.-based pharmaceutical companies and its partnership with Heidelberg Engineering to distribute RetinAI’s Disease AI Apps for research use in the U.S. The Boston office will be RetinAI’s second location, in addition to its Bern headquarters.

RetinAI will attend EURETINA 2022 from September 1st to 4th in Hamburg

RetinAI will attend the 22nd EURETINA Congress, from September 1st to 4th, at the CCH (Congress Centre Hamburg) in Hamburg, Germany. EURETINA 2022 attendees will get first-hand insights on the company’s two new products: Our new data management platform, Discovery CORE, designed to share data in a privacy-preserving and secure manner across a network of collaborators, fostering and facilitating knowledge network building, vendor-neutral collaborative data analysis & management, education, training and teleophthalmology. Our Disease Evaluation Apps on Heidelberg Engineering’s secure data workflow solution, called AppWay, for connecting to AI applications.

RetinAI attends OIS Retina Innovation Summit and ASRS 2022 Annual Meeting from July 13th to 16th in New York

RetinAI will attend the OIS Retina Innovation Summit on July 13th at the Edison Ballroom NYC, and the ASRS 2022 Annual Meeting, from July 14th to 16th, at the Javits Convention Center in New York. ASRS attendees who visit RetinAI at Booth #625 will benefit from learning and seeing live demos on RetinAIs latest products and services.

RetinAI announces multi-year software license and services agreement for RetinAI Discovery® UNITY platform

RetinAI announces a multi-year license and services agreement with Novartis AG (“Novartis”) for its Discovery® UNITY platform. Discovery UNITY is RetinAI’s top of the line enterprise-wide solution to aggregate imaging data for global organizations, including data from clinical and real-world evidence studies, with AI that can be applied to improve understanding of patient populations and outcomes at scale.

Latest updates

RetinAI on the Top100 Swiss Startups [SEPTEMBER’18]

This year RetinAI has been selected as one of the TOP 100 of Swiss Startups 2018! It’s a great recognition for the team. We are proud of the results we are achieving and we are extremely excited about the future ahead!

Welcome to the new RetinAI [SEPTEMBER'18]

There's nothing permanent except change - Heraclitus. We are incredibly pleased to announce our new logo at RetinAI! This new image reflects our values, strengths and willingness to connect the anatomical and digital worlds to provide a better healthcare for the patient.

Venture Leaders China 2018 [SEPTEMBER'18]

The 10-day business roadshow in China with VentureLab is only a week away! Get to know the Venture Leaders China team member Carlos Ciller, CEO & co-founder of RetinAI before the trip begins! Source: VentureLab.

AGEFI - RetinAI [JULY'18]

RetinAI is honoured to appear in the first page of AGEFI this 5th of July! Another opportunity to highlight how advanced machine learning and artificial intelligence are changing the world of ophthalmic care for the benefit of the patient and healthcare systems worldwide.

Contact us for more informations! We are happy to hear from you!